<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155411</url>
  </required_header>
  <id_info>
    <org_study_id>20191103</org_study_id>
    <nct_id>NCT04155411</nct_id>
  </id_info>
  <brief_title>Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP</brief_title>
  <official_title>Efficacy and Safety of Dasatinib 70 mg as First-Line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Second People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy and safety of dasatinib 70 mg once daily&#xD;
      as first line therapy in patients with early chronic phase (CP) chronic myeloid leukemia&#xD;
      (CML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, single-arm, prospective, open-label study to detect the efficacy and safety of&#xD;
      70mg dasatinib by measuring rates of major molecular response (MMR) at 12 months in patients&#xD;
      with CML-CP in China. Approximately 65 Patients will be recruited consecutively from the&#xD;
      study sites during the enrollment period and will be given dasatinib 70 mg QD. The duration&#xD;
      of patient participation will be 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who achieve and maintain MMR at 12 months using RQ-PCR test</measure>
    <time_frame>12 months</time_frame>
    <description>Major molecular response (MMR) is defined as BCR-ABL1 ≤ 0.1%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with MR 4.0 at 12 months.</measure>
    <time_frame>12 months</time_frame>
    <description>Molecular response (MR) 4.0 is defined as BCR-ABL transcripts ≤ 0.01%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with MR 4.5 at 12 months.</measure>
    <time_frame>12 months</time_frame>
    <description>Molecular response (MR) 4.5 is defined as BCR-ABL transcripts ≤ 0.0032%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Complete cytogenetic response (CCyR) at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>defined as 0% Ph+ metaphases, or FISH ≤2%, or BCR-ABL transcripts (IS) ≤1%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs) to dasatinib</measure>
    <time_frame>18 months</time_frame>
    <description>Evaluation of adverse events (AEs), serious AEs (SAEs), and clinically relevant changes in laboratory tests according to laboratory reference ranges</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Dasatinib</condition>
  <condition>BCR-ABL</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Dasatinib 70 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>70 mg of Dasatinib orally daily for 12 months</description>
    <arm_group_label>Dasatinib 70 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Diagnosis of Ph+ or BCR-ABL positive CML-CP within 6 months.&#xD;
&#xD;
          -  ECOG performance of 0-2.&#xD;
&#xD;
          -  Adequate end organ function defined as the following: total bilirubin &lt;1.5x ULN, SGPT&#xD;
             &lt;2.5x ULN, creatinine &lt;1.5x ULN.&#xD;
&#xD;
          -  Patients must sign an informed consent form (ICF) indicating they are aware of the&#xD;
             investigational nature of this study, in keeping with the policies of the hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any TKI treatments.&#xD;
&#xD;
          -  History of Pulmonary arterial hypertension and Pleural effusion&#xD;
&#xD;
          -  NYHA cardiac class 3-4 heart disease.&#xD;
&#xD;
          -  Cardiac symptoms - Patients meeting the following criteria are not eligible unless&#xD;
             cleared by a cardiologist:&#xD;
&#xD;
          -  Uncontrolled angina within 12 months.&#xD;
&#xD;
          -  Diagnosed or suspected congenital long QT syndrome.&#xD;
&#xD;
          -  Any history of clinically significant ventricular arrhythmias (such as ventricular&#xD;
             tachycardia, ventricular fibrillation, or torsades de pointes).&#xD;
&#xD;
          -  Prolonged QTc interval on pre-entry electrocardiogram (&gt;450 msec).&#xD;
&#xD;
          -  Patients with active uncontrolled psychiatric disorders including: psychosis, major&#xD;
             depression, and bipolar disorders.&#xD;
&#xD;
          -  Women of pregnancy potential must practice an effective method of birth control,&#xD;
             unless otherwise instructed, during the course of the study in a manner such that risk&#xD;
             of failure is minimized.&#xD;
&#xD;
          -  Pregnant or breast-feeding women are excluded.&#xD;
&#xD;
          -  Patients in late chronic phase (i.e. time from diagnosis to treatment &gt;12 months),&#xD;
             accelerated phase (except as noted in inclusion criteria 2) or blast phase are&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xin Du</last_name>
    <phone>075583366388</phone>
    <email>duxingz@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xin Du</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Du, PHD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dasatinib, CML-CP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

